A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed by Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old (PAY).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PAY
Most Recent Events
- 12 May 2020 Biomarkers information updated
- 25 Dec 2009 New trial record